2-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-ylmethyl)-10,11-dihydro-5H-dibenz[b,f]azepine | 150802-42-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 2-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-ylmethyl)-10,11-dihydro-5H-dibenz[b,f]azepine
• 英文别名: 2-(5,7-Dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl-10,11-dihydro-5H-dibenz[b,f]azepine；2-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl-10,11-dihydro-5H-dibenzo[b,f]azepine；3-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]-6,11-dihydro-5H-benzo[b][1]benzazepine
• CAS: 150802-42-9
• 化学式: C₂₅H₂₆N₄
• 分子量: 382.508
• InChiKey: ACMKSKQXSHCIPR-UHFFFAOYSA-N

物化性质

• 沸点：
  597.6±50.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  42.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-ylmethyl)-10,11-dihydro-5H-dibenz[b,f]azepine 在 羟胺 作用下， 以 乙醇 、 水 、 溶剂黄146 为溶剂， 反应 25.0h， 生成 2-(2-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N'-hydroxyacetimidamide
  参考文献：
  名称：

  TRICYCLIC COMPOUNDS

  摘要：

  公开号：

  EP1988091B1
• 作为产物：
  描述：

  1-(10,11-dihydro-5H-dibenz[b,f]azepin-2-ylmethyl)-1-methylpiperidinium iodide 、 咪唑并二甲基吡啶 在 lithium hydroxide 作用下， 以 N,N-二甲基甲酰胺 、 水 为溶剂， 反应 10.25h， 以46%的产率得到2-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-ylmethyl)-10,11-dihydro-5H-dibenz[b,f]azepine
  参考文献：
  名称：

  TRICYCLIC COMPOUNDS

  摘要：

  公开号：

  EP1988091B1

文献信息

• Identification of a Potent and Selective GPR4 Antagonist as a Drug Lead for the Treatment of Myocardial Infarction
  作者：Hayato Fukuda、Saki Ito、Kenji Watari、Chihiro Mogi、Mitsuhiro Arisawa、Fumikazu Okajima、Hitoshi Kurose、Satoshi Shuto

  DOI：10.1021/acsmedchemlett.6b00014

  日期：2016.5.12

  infarction due the decreased tissue pH. We are interested in GPR4 antagonists as potential effective pharmacologic tools and/or drug leads for the treatment of myocardial infarction. We investigated the structure-activity relationship of a known GPR4 antagonist 1 as a lead compound to identify 3b as the first potent and selective GPR4 antagonist, whose effectiveness was demonstrated in a mouse myocardial

  GPR4是一种pH敏感的G蛋白偶联受体，在内皮细胞中高度表达，由于组织pH降低，可能在心肌梗塞中被激活。我们对GPR4拮抗剂作为治疗心肌梗死的潜在有效药理工具和/或药物线索感兴趣。我们调查了已知的GPR4拮抗剂1作为前导化合物的结构-活性关系，以确定3b是第一个有效的和选择性的GPR4拮抗剂，其有效性已在小鼠心肌梗死模型中得到证实。
• PREVENTIVE AND/OR THERAPEUTIC DRUGS FOR ITCH
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1547616A1

  公开（公告）日：2005-06-29

  The present invention provides an agent for prevention and/or treatment of itching comprising a substance capable of suppressing the function involved in signal transduction of GPR4 as an active ingredient. It also provides a nitrogen-containing tricyclic compound represented by the formula (I) or a quaternary ammonium salt thereof, or a pharmaceutically acceptable salt thereof; [wherein R1 represents substituted or unsubstituted lower alkyl, etc.; R2 represents hydrogen, substituted or unsubstituted lower alkyl, etc.; R3 and R4 are the same or different and each represents hydrogen, lower alkyl, etc.; n represents 0 or 1; X represents -(CH2)2-, etc.; and Y represents the formula (II); (wherein W represents CH or a nitrogen atom; Z1 and Z2 are the same or different and each represents hydrogen, substituted or unsubstituted lower alkyl, etc.; and Z3 represents hydrogen, substituted or unsubstituted lower alkyl, etc.)]

  本发明提供了一种用于预防和/或治疗瘙痒的药剂，包括一种能够抑制参与GPR4信号转导功能的物质作为活性成分。它还提供了一种由式（I）表示的含氮三环化合物或其季铵盐，或其药用可接受盐；[其中R1代表取代或未取代的较低烷基等；R2代表氢、取代或未取代的较低烷基等；R3和R4相同或不同，各自代表氢、较低烷基等；n代表0或1；X代表-(CH2)2-等；Y代表式（II）；（其中W代表CH或氮原子；Z1和Z2相同或不同，各自代表氢、取代或未取代的较低烷基等；Z3代表氢、取代或未取代的较低烷基等）]
• Preventive and/or therapeutic drugs for asthma
  申请人：Saki Mayumi

  公开号：US20060239999A1

  公开（公告）日：2006-10-26

  The present invention provides an agent for prevention and/or treatment of asthma comprising a substance capable of suppressing the function involved in signal transduction of GPR4 as an active ingredient. It also provides an agent for prevention and/or treatment of asthma which comprises a nitrogen-containing tricyclic compound represented by the formula (I) or a quaternary ammonium salt thereof, or a pharmaceutically acceptable salt thereof; [wherein R 1 represents a substituted or unsubstituted lower alkyl, or the like; R 2 represents hydrogen, a substituted or unsubstituted lower alkyl, or the like; R 3 and R 4 are the same or different and each represents hydrogen, lower alkyl, or the like; n represents 0 or 1; X represents —(CH 2 ) 2 —, or the like; and Y represents the formula (II) (wherein W represents CH or a nitrogen atom; Z 1 and Z 2 are the same or different and each represents hydrogen, a substituted or unsubstituted lower alkyl, or the like; and Z 3 represents hydrogen, a substituted or unsubstituted lower alkyl, or the like)] as an active ingredient.

  本发明提供了一种用于预防和/或治疗哮喘的药剂，其包括一种能够抑制GPR4信号转导功能的物质作为活性成分。还提供了一种用于预防和/或治疗哮喘的药剂，其包括式(I)所表示的含氮三环化合物或其季铵盐，或其药学上可接受的盐；[其中R1表示取代或未取代的低碳基等；R2表示氢、取代或未取代的低碳基等；R3和R4相同或不同，每个表示氢、低碳基等；n表示0或1；X表示—(CH2)2—等；Y表示式(II)（其中W表示CH或氮原子；Z1和Z2相同或不同，每个表示氢、取代或未取代的低碳基等；Z3表示氢、取代或未取代的低碳基等）]作为活性成分。
• Preventive and/or trerapeutic drgs for itch
  申请人：Saki Mayumi

  公开号：US20060252679A1

  公开（公告）日：2006-11-09

  The present invention provides an agent for prevention and/or treatment of itching comprising a substance capable of suppressing the function involved in signal transduction of GPR4 as an active ingredient. It also provides a nitrogen-containing tricyclic compound represented by the formula (I) or a quaternary ammonium salt thereof, or a pharmaceutically acceptable salt thereof; [wherein R 1 represents substituted or unsubstituted lower alkyl, etc.; R 2 represents hydrogen, substituted or unsubstituted lower alkyl, etc.; R 3 and R 4 are the same or different and each represents hydrogen, lower alkyl, etc.; n represents 0 or 1; X represents —(CH 2 ) 2 —, etc.; and Y represents the formula (II); (wherein W represents CH or a nitrogen atom; Z 1 and Z 2 are the same or different and each represents hydrogen, substituted or unsubstituted lower alkyl, etc.; and Z 3 represents hydrogen, substituted or unsubstituted lower alkyl, etc.)]

  本发明提供了一种用于预防和/或治疗瘙痒的药剂，其包括一种能够抑制GPR4信号传导功能的物质作为活性成分。它还提供了一种氮杂三环化合物，其表示为式(I)或其季铵盐，或其药学上可接受的盐；其中，R1表示取代或未取代的低碳基等；R2表示氢，取代或未取代的低碳基等；R3和R4相同或不同，每个表示氢，低碳基等；n表示0或1；X表示—(CH2)2—等；Y表示式(II)；(其中，W表示CH或氮原子；Z1和Z2相同或不同，每个表示氢，取代或未取代的低碳基等；Z3表示氢，取代或未取代的低碳基等。)
• Tricyclic compounds
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US08242151B2

  公开（公告）日：2012-08-14

  The present invention provides a PPAR γ agonist comprising, as an active ingredient, a tricyclic compound represented by the formula (I) (wherein R1 represents lower alkyl optionally having substituent(s) or the like, R2 and R3 are the same or different and each represents lower alkyl optionally having substituent(s) or the like, R4 and R5 are the same or different and each represents a hydrogen atom or the like, Q1-Q2-Q3 represents CH═CH—CH═CH or the like, Y represents a single bond or the like, Z1-Z2 represents C═CR13 (wherein R13 represents a hydrogen atom or the like), or the like, and A represents —COOH or the like), or a pharmaceutically acceptable salt thereof and the like.

  本发明提供了一种PPARγ激动剂，其作为活性成分包含由式（I）表示的三环化合物（其中R1表示较低的烷基，可选地具有取代基或类似物，R2和R3相同或不同，且每个表示较低的烷基，可选地具有取代基或类似物，R4和R5相同或不同，且每个表示氢原子或类似物，Q1-Q2-Q3表示CH═CH—CH═CH或类似物，Y表示单键或类似物，Z1-Z2表示C═CR13（其中R13表示氢原子或类似物）或类似物，A表示—COOH或类似物），或其药学上可接受的盐等。